Abstract:
Even though the introduction of DTG based ART has provided a potent treatment option for persons living
with HIV, there is growing evidence from clinical settings that use of DTG can result in hyperglycemia,
serious neurologic and neuropsychiatric side effects. Moreover, there is currently insufficient information
regarding the safety of DTG-based combination regimen, including the types and frequency of suspected
adverse drug events (ADEs) experienced and reported in Ethiopian population. Hence, the Ethiopian Food
and Drug Authority (EFDA) conducted a Cohort Event Monitoring (CEM) on DTG based regimen in
collaboration with stakeholders and partners among patients receiving ART service in selected health
facilities of Addis Ababa.
